Published in Int J Exp Pathol on August 12, 2014
Peromyscus mice as a model for studying natural variation. Elife (2015) 0.91
Broad diversity of host responses of the white-footed mouse Peromyscus leucopus to Borrelia infection and antigens. Ticks Tick Borne Dis (2015) 0.79
In vitro culture of ovarian follicles from Peromyscus. Semin Cell Dev Biol (2016) 0.75
Hematopoietic Aging Biomarkers in Peromyscus leucopus Mice. J Aging Sci (2017) 0.75
Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood (1997) 2.59
Genetic analysis of the diversity and origin of hantaviruses in Peromyscus leucopus mice in North America. J Virol (1998) 1.87
Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol (2010) 1.78
Molecular linkage of hantavirus pulmonary syndrome to the white-footed mouse, Peromyscus leucopus: genetic characterization of the M genome of New York virus. J Virol (1995) 1.50
Serologic analyses of Peromyscus leucopus, a rodent reservoir for Borrelia burgdorferi, in northeastern United States. J Clin Microbiol (1988) 1.37
Longevity is associated with increased vascular resistance to high glucose-induced oxidative stress and inflammatory gene expression in Peromyscus leucopus. Am J Physiol Heart Circ Physiol (2009) 1.13
Deer Mice As Laboratory Animals. ILAR J (1998) 1.08
Longevity, aging and comparative cellular and molecular biology of the house mouse, Mus musculus, and the white-footed mouse, Peromyscus leucopus. Birth Defects Orig Artic Ser (1978) 1.04
Longitudinal study of infection with Borrelia burgdorferi in a population of Peromyscus leucopus at a Lyme disease-enzootic site in Maryland. Am J Trop Med Hyg (1999) 1.03
Quantitative trait loci regulating relative lymphocyte proportions in mouse peripheral blood. Blood (2002) 1.00
Histopathology of Peromyscus leucopus naturally infected with pathogenic NY-1 hantaviruses: pathologic markers of HPS viral infection in mice. Lab Invest (1996) 0.98
Analysis of Borrelia burgdorferi sequentially isolated from Peromyscus leucopus captured at a Lyme disease enzootic site. J Infect Dis (1995) 0.95
Reduced mitochondrial ROS, enhanced antioxidant defense, and distinct age-related changes in oxidative damage in muscles of long-lived Peromyscus leucopus. Am J Physiol Regul Integr Comp Physiol (2013) 0.94
Gerontological data of C57BL/6J mice. II. Changes in blood cell counts in the course of natural aging. J Gerontol (1976) 0.90
Detection of Borrelia burgdorferi in urine of Peromyscus leucopus by inhibition enzyme-linked immunosorbent assay. J Clin Microbiol (1994) 0.88
Effects of genetic captive-breeding protocols on sperm quality and fertility in the white-footed mouse. Biol Reprod (2010) 0.88
Accelerated wound repair in old deer mice (Peromyscus maniculatus) and white-footed mice (Peromyscus leucopus). J Gerontol (1987) 0.86
Evolution of Peromyscus leucopus mice in response to a captive environment. PLoS One (2013) 0.86
Evidence for a brain site of melatonin action in the white-footed mouse, Peromyscus leucopus. Neuroendocrinology (1982) 0.85
A brain site for the antigonadal action of melatonin in the white-footed mouse (Peromyscus leucopus): involvement of the immunoreactive GnRH neuronal system. Neuroendocrinology (1987) 0.84
Hematology values from clinically healthy Peromyscus leucopus. J Zoo Wildl Med (1999) 0.83
Melatonin acts in the brain to mediate seasonal steroid inhibition of luteinizing hormone secretion in the white-footed mouse (Peromyscus leucopus). Proc Soc Exp Biol Med (1988) 0.83
Immunological, hematological, and biochemical responses in immature white-footed mice following maternal Aroclor 1254 exposure: A possible bioindicator. Arch Environ Contam Toxicol (1999) 0.83
Effects of advancing age on the hypothalamic-pituitary-ovarian axis of the female white-footed mouse (Peromyscus leucopus). Exp Aging Res (1980) 0.83
Survival and reproduction in Peromyscus leucopus in the laboratory: viable model for aging studies. Growth Dev Aging (1992) 0.82
Melatonin receptors and signal transduction in melatonin-sensitive and melatonin-insensitive populations of white-footed mice (Peromyscus leucopus). Brain Res (1990) 0.79
Aging and ovarian function in the white-footed mouse (Peromyscus leucopus) with specific reference to the development of preovulatory follicles. Exp Aging Res (1980) 0.77
Age changes in rhythms of energy metabolism, activity, and body temperature in Mus and Peromyscus. Adv Exp Med Biol (1978) 0.77
PEROMYSCUS LEUCOPUS: AN INTERESTING SUBJECT FOR STUDIES OF SOCIALLY INDUCED STRESS RESPONSES. Science (1964) 0.77
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med (2005) 7.09
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Telomere diseases. N Engl J Med (2009) 5.68
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
Hematopoietic-specific microRNA expression in human cells. Leuk Res (2005) 3.95
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med (2011) 3.82
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann Intern Med (2005) 2.79
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet (2003) 2.76
Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood (2003) 2.73
Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet (2009) 2.73
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 2.47
How I treat acquired aplastic anemia. Blood (2012) 2.44
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation (2005) 2.13
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood (2009) 2.12
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood (2002) 2.10
Telomere maintenance and human bone marrow failure. Blood (2008) 2.09
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood (2013) 1.97
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood (2008) 1.95
Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood (2010) 1.91
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol (2006) 1.88
Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol (2006) 1.82
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol (2010) 1.79
Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology (2011) 1.77
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica (2009) 1.73
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood (2004) 1.70
Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol (2006) 1.68
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood (2006) 1.64
Prevalence of physical activity among Chinese adults: results from the International Collaborative Study of Cardiovascular Disease in Asia. Am J Public Health (2005) 1.63
Mutations in the SBDS gene in acquired aplastic anemia. Blood (2007) 1.62
Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol (2003) 1.59
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest (2008) 1.58
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood (2006) 1.57
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol (2008) 1.49
Blood pressure response to potassium supplementation is associated with genetic variation in endothelin 1 and interactions with E selectin in rural Chinese. J Hypertens (2010) 1.47
Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood (2004) 1.46
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood (2007) 1.44
A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol (2004) 1.42
Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol (2008) 1.41
Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol (2004) 1.40
Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol (2007) 1.40
Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2002) 1.39
The epidemiology of aplastic anemia in Thailand. Blood (2005) 1.38
Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A (2006) 1.36
Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood (2004) 1.33
Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood (2005) 1.30
Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol (2007) 1.28
Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy. Blood (2010) 1.27
Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica (2010) 1.25
Infections in patients with aplastic anemia. Semin Hematol (2009) 1.25
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med (2002) 1.25
Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr (2008) 1.22
Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer (2009) 1.22
Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica (2009) 1.20
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood (2002) 1.19
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Nonisotopic detection of microRNA using digoxigenin labeled RNA probes. Mol Cell Probes (2006) 1.18
Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis (2011) 1.16
The FANCG Fanconi anemia protein interacts with CYP2E1: possible role in protection against oxidative DNA damage. Carcinogenesis (2002) 1.16
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol (2008) 1.15
Telomere length is inherited with resetting of the telomere set-point. Proc Natl Acad Sci U S A (2010) 1.15
Effects of dietary restriction on hematopoietic stem-cell aging are genetically regulated. Blood (2007) 1.14
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14
Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs. J Clin Invest (2013) 1.13
Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J Infect Dis (2003) 1.13
Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood (2004) 1.12